News

Fox Chase Cancer Center's Robert Young Appointed Chairman of the National Cancer Institute's Board of Scientific Advisors

PHILADELPHIA (December 4, 2007)—Robert C. Young, M.D., has been appointed to a second term as chairman of the National Cancer Institute's Board of Scientific Advisors by NCI director John E. Niederhuber, M.D. Young, chancellor at Fox Chase Cancer Center in Philadelphia, has served as a member of the Board for 11 years and has been chairman for three years. The reappointment is for a two-year term.

The Board of Scientific Advisors provides scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the NCI's extramural research programs as well as concept review of extramural program initiatives.

Young has a distinguished career in national leadership roles within the cancer community. Most recently, he served as president of Fox Chase Cancer Center, stepping down in 2006 after 18 years of service. Young is also past president of the American Cancer Society, the American Society of Clinical Oncology (ASCO) and the International Gynecologic Cancer Society.

Young is internationally known for his work in the treatment of lymphoma and ovarian cancer. He received ASCO's Distinguished Service Award for Scientific Leadership in 2004 and was co-recipient of the 2002 Bristol-Myers Squibb Award for Distinguished Achievement in Cancer Research for his research in ovarian cancer.

Young recently completed his appointment to the National Cancer Policy Board at the Institute of Medicine. A fellow of the American College of Physicians, Young is also a member of the prestigious American Society of Clinical Investigation.

Born in Columbus, Ohio, Young received his B.Sc. degree in zoology in 1960 from Ohio State University and his M.D. in 1965 from Cornell University Medical College. Following his internship at New York Hospital, he completed his residency at NCI and Yale-New Haven Medical Center. He is board-certified in internal medicine, hematology and oncology by the American Board of Internal Medicine.